Skip to main content
Equibles

UBS Group AG

Position in JNJ — Johnson & Johnson

CIK 1610520 ZURICH, V8
Back to JNJ Full portfolio

Position in JNJ

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$2,803,039,201
+$307,471,315 QoQ
Shares Held
11,036,891
+8.1% QoQ
Ownership
0.458%
of shares outstanding
% of Portfolio
0.58%
of 13F equity value
Holder Rank
#31
of 4,676 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 25% Shared 0% None 75%

Common Shares in JNJ Over Time

Shares Held

Position Value (USD)

Derivatives in JNJ

reported options exposure · as of Jun 30, 2026
CallValue
$70,324,293
CallShares
276,900
PutValue
$115,670,128
PutShares
455,448

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

UBS Group AG holds $17,056,271,930 across 20 Drug Manufacturers - General names. JNJ ranks #3 (16.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 3,865,931 $4,636,914,000
2 ABBV
AbbVie Inc.
 12,845,120 $3,232,345,993
3 JNJ
Johnson & Johnson
This page 		11,036,891 $2,803,039,201
4 MRK
Merck & Co., Inc.
 13,744,783 $1,766,204,613
5 AMGN
Amgen Inc
 3,308,695 $1,198,144,628
6 AZN
Astrazeneca PLC
 5,297,462 $1,004,504,738
7 GILD
Gilead Sciences, Inc.
 4,503,294 $568,946,162
8 BMY
Bristol Myers Squibb Co
 8,876,439 $511,460,413

All Filings in JNJ

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $115,670,128 455,448
2026-06-30 $70,324,293 276,900
2026-06-30 $2,803,039,201 11,036,891
2026-03-31 $2,495,567,886 10,209,327
2026-03-31 $99,755,964 408,100
2026-03-31 $133,353,753 545,548
2025-12-31 $122,948,167 594,096
2025-12-31 $138,935,468 671,348
2025-12-31 $2,066,249,016 9,984,291
2025-09-30 $1,928,421,950 10,400,291
2025-09-30 $143,819,910 775,644
2025-09-30 $114,996,556 620,195
2025-06-30 $1,915,508,978 12,540,157
2025-06-30 $80,611,063 527,732
2025-06-30 $102,456,146 670,744
2025-03-31 $135,996,096 820,044
2025-03-31 $1,974,992,368 11,909,023
2025-03-31 $117,529,978 708,695
2024-12-31 $122,918,901 849,944
2024-12-31 $163,926,046 1,133,495
2024-12-31 $2,023,221,791 13,989,917
2024-09-30 $147,392,759 909,495
2024-09-30 $1,880,130,494 11,601,447
2024-09-30 $170,996,636 1,055,144
2024-06-30 $1,506,592,426 10,307,830
2024-06-30 $76,986,710 526,729
2024-06-30 $88,206,829 603,495
2024-03-31 $114,710,529 725,144
2024-03-31 $79,948,435 505,395
2024-03-31 $1,587,062,368 10,032,634
2023-12-31 $1,368,888,785 8,733,500
2023-12-31 $152,348,301 971,981
2023-12-31 $109,300,601 697,337
2023-09-30 $82,298,300 528,400
2023-09-30 $1,513,570,088 9,717,946
2023-09-30 $46,693,850 299,800
2023-06-30 $42,030,493 253,930
2023-06-30 $1,473,400,939 8,901,649
2023-06-30 $74,517,104 450,200
2023-03-31 $22,836,150 147,330
2023-03-31 $1,674,964,100 10,806,220
2023-03-31 $66,076,500 426,300
2022-12-31 $2,192,999,515 12,414,376
2022-12-31 $137,698,675 779,500
2022-12-31 $40,876,810 231,400
2022-09-30 $26,273,188 160,830
2022-09-30 $1,709,903,980 10,467,091
2022-09-30 $108,993,792 667,200
2022-06-30 $1,890,555,870 10,650,419
2022-06-30 $16,188,912 91,200

Report a Problem

Category
Description
Email (optional, for follow-up)